AKER has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AKER has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-14), Akers Biosciences's share price is $4.94. Akers Biosciences's Book Value per Share for the quarter that ended in Dec. 2020 was $1.96. Hence, Akers Biosciences's PB Ratio of today is 2.52.
The historical rank and industry rank for Akers Biosciences's PB Ratio or its related term are showing as below:
The historical data trend for Akers Biosciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akers Biosciences Annual Data | |||||||||||||||||||||
Trend | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | |||||||||||
PB Ratio | Get a 7-Day Free Trial | 6.12 | 2.04 | 4.84 | 1.19 | 2.03 |
Akers Biosciences Quarterly Data | ||||||||||||||||||||
Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | |
PB Ratio | Get a 7-Day Free Trial | 1.19 | 1.95 | 2.74 | 1.90 | 2.03 |
For the Medical Instruments & Supplies subindustry, Akers Biosciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Akers Biosciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Akers Biosciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Akers Biosciences's PB Ratio for today is calculated as follows:
PB Ratio | = | Share Price | / | Book Value per Share (Q: Dec. 2020) |
= | 4.94 | / | 1.958 | |
= | 2.52 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PB Ratio | = | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock) |
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Akers Biosciences (NAS:AKER) PB Ratio Explanation
Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Thank you for viewing the detailed overview of Akers Biosciences's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Billy Joe White | director | 191 OTTO ST., PORT TOWNSEND WA 98368 |
Joshua Silverman | director | IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017 |
Christopher C Schreiber | director, officer: Exec. Chairman and President | AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086 |
Robert C Schroeder | director | 37 MAIN STREET, COLD SPRING HARBOR, NEW YORK NY 11724 |
Stuart M Benson | officer: Chief Financial Officer | EMPIRE STATE BUILDING, 350 5TH AVE., SUITE 7520, NEW YORK NY 10118 |
Hudson Bay Capital Management Lp | 10 percent owner | 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830 |
Sander Gerber | 10 percent owner | C/O HUDSON BAY CAPITAL MANAGEMENT, L.P., 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830 |
Howard Yeaton | officer: CEO, CFO | 79 LLOYD ROAD, HOHOKUS NJ 07423 |
John J Gormally | director, officer: Chief Executive Officer | 80 WALSH DRIVE, MAHWAH NJ 07430 |
Gary M Rauch | officer: VP - Finance, Treasurer | 842 ST REGIS COURT, WEST DEPTFORD NJ 08051 |
Tarbox Richard C Iii | director | AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086 |
Brandon Thomas Knox | director | 771 EAGLE ROAD, VILLANOVA PA 19085 |
Akers Raymond Francis Jr | director, officer: Executive Chairman, Secretary | 171 E. ESSEX AVE, SEWELL NJ 08080 |
Thomas J Knox | director | 1717 ARCH STREET, SUITE 3820, PHILADELPHIA PA 19103 |
Robert E Andrews | director | 215 4TH AVENUE, HADDON HEIGHTS NJ 08035 |
From GuruFocus
By PRNewswire PRNewswire • 11-17-2020
By Marketwired Marketwired • 04-06-2020
By Marketwired Marketwired • 11-13-2020
By Business Wire Business Wire • 02-18-2021
By Business Wire Business Wire • 02-17-2021
By Business Wire Business Wire • 02-23-2021
By Marketwired Marketwired • 07-07-2020
By Business Wire Business Wire • 11-18-2020
By PRNewswire PRNewswire • 12-20-2020
By PRNewswire PRNewswire • 12-05-2020
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.